Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Amarin Initiated With BUY At Suntrust $15PT

|Includes: Amarin Corporation PLC (AMRN)

Suntrust starts AMRN with BUY and $15 short term price target, citing traction on Vascepa launch and likelihood of wider indication expansion. Does not fully bake wider indication in price target at this time.

Amarin set to soar, my 12-mo target remains $28-32, with AMRN scoring NCE and ultimately being acquired by a larger pharma company.